Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sever

Showing results (21-30 of 113) with videos related to

Pageof 12
Sort By:
Journal of Hypertension|July 14, 2025
'4 Ss' for successful blood pressure controlIan B Wilkinson, Sarah Partridge, Peter Sever
Lancet (London, England)|June 20, 2008
Systolic pressure is all that mattersBryan Williams, Lars H Lindholm, Peter Sever
JACC. Heart Failure|March 14, 2014
Is dual renin-angiotensin-system blockade associated with increased risk of stroke?Harikrishna Makani, Sripal Bangalore, Peter Sever, et al.
The British Journal of Cardiology|March 18, 2026
Long-term blood pressure variability: an emerging cardiovascular risk factorAllis Lai, Lawrence Lam, Akshita Raminemi, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|September 4, 2018
A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidoneMichael A Weber, Peter Sever, Attila Juhasz, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 8, 2023
Amlodipine in the current management of hypertensionJi-Guang Wang, Biff F Palmer, Katherine Vogel Anderson, et al.
European Heart Journal|June 1, 2021
Lowering systolic blood pressure to 120 mmHg or The Lancet's true gritFranz H Messerli, Jana Brguljan, Emrush Rexhaj, et al.
Journal of Hypertension|November 6, 2025
The impact of blood pressure variability on cardiovascular and renal outcomes in patients with and without diabetes: insights from the Anglo-Scandinavian Cardiac Outcomes TrialSomayeh Rostamian, Amit Kaura, Cono Ariti, et al.
Plos One|November 9, 2022
Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK BiobankHolly Pavey, Spoorthy Kulkarni, Angela Wood, et al.
Lancet (London, England)|May 7, 2017
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phaseAjay Gupta, David Thompson, Andrew Whitehouse, et al.
Pageof 12

Showing results (21-30 of 113) with videos related to

Sort By:
Pageof 12
Journal of Hypertension|July 14, 2025
'4 Ss' for successful blood pressure controlIan B Wilkinson, Sarah Partridge, Peter Sever
Lancet (London, England)|June 20, 2008
Systolic pressure is all that mattersBryan Williams, Lars H Lindholm, Peter Sever
JACC. Heart Failure|March 14, 2014
Is dual renin-angiotensin-system blockade associated with increased risk of stroke?Harikrishna Makani, Sripal Bangalore, Peter Sever, et al.
The British Journal of Cardiology|March 18, 2026
Long-term blood pressure variability: an emerging cardiovascular risk factorAllis Lai, Lawrence Lam, Akshita Raminemi, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|September 4, 2018
A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidoneMichael A Weber, Peter Sever, Attila Juhasz, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 8, 2023
Amlodipine in the current management of hypertensionJi-Guang Wang, Biff F Palmer, Katherine Vogel Anderson, et al.
European Heart Journal|June 1, 2021
Lowering systolic blood pressure to 120 mmHg or The Lancet's true gritFranz H Messerli, Jana Brguljan, Emrush Rexhaj, et al.
Journal of Hypertension|November 6, 2025
The impact of blood pressure variability on cardiovascular and renal outcomes in patients with and without diabetes: insights from the Anglo-Scandinavian Cardiac Outcomes TrialSomayeh Rostamian, Amit Kaura, Cono Ariti, et al.
Plos One|November 9, 2022
Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK BiobankHolly Pavey, Spoorthy Kulkarni, Angela Wood, et al.
Lancet (London, England)|May 7, 2017
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phaseAjay Gupta, David Thompson, Andrew Whitehouse, et al.
Pageof 12